Republican Sen. Jeff Sessions and Tom Price are two recent cabinet nominations from President-elect Donald Trump. Their track records show their hard-line on drugs, specifically marijuana, and this has people in the cannabis industry wondering if Trump is reversing the progress made in recent years. Between the two, Sessions’ appointment would be frustrating. For the hope of the cannabis industry we must anticipate that Sessions, if appointed, will take a positive outlook on medicinal marijuana and see the positive benefits—both socially and economically—it provides its patients and the rest of the United States.
Washington, DC, along with 28 other states, has legalized marijuana for either recreational or medicinal use and they have all seen some incredible benefits. There are reduced violent crime rates, no increase in youth marijuana use or traffic fatalities, as well as an increase in tax revenue. Colorado alone has shown what figures it can bring in from marijuana sales. If Trump is truly a successful businessman then bringing on the likes of Sessions and Price will clearly derail any progress United States made in the past few years. His main concern during elections was bringing in new jobs for the working class, and yet the most booming industry in America today might be overlooked by our president-elect.
Although the Trump administration is slowly looking like it might calm down progress of the medical marijuana industry, those cultivators and businessmen who are wholeheartedly in it for the long haul will continue to keep fighting even if our president-elect won’t.
With 19 states currently selling recreational cannabis, it may be tempting to forgo a medical card, even if you qualify as a patient. While recreational marijuana is accessible in many states for those of age, there are still some benefits to having a medical marijuana card and purchasing medical marijuana instead of recreational pot. For…
A type of arthritis known as ‘gout’ is common, complex, and can affect anyone. Patients who suffer from gout are plagued by sudden and severe spikes of pain, swelling, and more. This condition affects certain joints but is often the joint at the base of the big toe. Gout is triggered by arthropathy which is…
In 1970 cannabis was federally placed as a Schedule I drug in the US, a category that is tightly restricted and reserved for drugs not medically accepted. When it comes to classifying drugs medically or recreationally, generally there are four broad categories according to the US federal government. Based on their properties and effects, a…
Veriheal does not support illegally consuming alternative therapeutic substances but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting psychedelic therapy. Cannabis and magic mushrooms for the win! According to recently published survey findings,…
In response to a significant increase in research on Schedule I controlled substances, the U.S. Drug Enforcement Administration (DEA) has proposed dramatically raised levels of legal cannabis and psychedelic production in 2022 for use in studies. After already increasing production quotas for 2021, the DEA is calling for a 60% increase in marijuana production. This…
Israeli cannabis company Tikun-Olam Cannbit has partnered with Israeli nutritional supplement company Ambrosia-SupHerb to produce and market a series of unique supplements…
We’ve all heard that cannabis has been around for thousands of years and used as an entheogen—a psychoactive substance used in a…
Since the coronavirus pandemic erupted in January 2020, researchers around the world have funneled their energy into carrying out virus-focused studies and…
